OPKO Health, Inc. Restructuring Charges
OPKO Health, Inc. (OPK) reported Restructuring Charges of $2.58 million for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2013-08-09
- OPKO Health, Inc. restructuring charges for the quarter ending 2013-06-30 was $2.58M, a 167.05% increase year-over-year.
- OPKO Health, Inc. restructuring charges for the quarter ending 2013-03-31 was $1.34M, a 17.48% increase year-over-year.
- OPKO Health, Inc. restructuring charges for the quarter ending 2012-12-31 was -$1.88M.
- OPKO Health, Inc. restructuring charges for the quarter ending 2012-09-30 was $556.00K.
- OPKO Health, Inc. restructuring charges for fiscal 2012 was $785.00K.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2013-06-30 | $2.58M 10-Q · filed 2013-08-09 | $3.92M 10-Q · filed 2013-08-09 | $2.04M derived: sum of 3 quarters · filed 2013-08-09 | $2.60M derived: sum of 4 quarters · filed 2013-08-09 |
| 2013-03-31 | $1.34M 10-Q · filed 2013-05-10 | -$536.00K derived: sum of 2 quarters · filed 2013-05-10 | $20.00K derived: sum of 3 quarters · filed 2013-05-10 | $985.00K derived: sum of 4 quarters · filed 2013-08-09 |
| 2012-12-31 | -$1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$1.32M derived: sum of 2 quarters · filed 2013-03-18 | -$359.00K derived: sum of 3 quarters · filed 2013-08-09 | $785.00K 10-K · filed 2013-03-18 |
| 2012-09-30 | $556.00K 10-Q · filed 2012-11-09 | $1.52M derived: sum of 2 quarters · filed 2013-08-09 | $2.67M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $965.00K 10-Q · filed 2013-08-09 | $2.11M 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | $1.14M 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |